U.S. Securities and Exchange
Commission
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) March 4, 2022
Commission File No. 001-33718
U.S. STEM CELL,
INC.
(Name of small business issuer as specified in its charter)
Florida
|
65-0945967
|
State of Incorporation
|
IRS Employer Identification No.
|
1560 Sawgrass Corporate Pkwy 4th Floor,
Sunrise, FL 33323
(Address of principal executive offices)
(954)
835-1500
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General
Instruction A.2. below):
☐ Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
USRM
|
OTC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1934
(§240.12b-2 of this chapter)
Emerging growth company ☐.
|
|
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Unless otherwise indicated or the context otherwise requires, all
references in this Form 8-K to “we,” “us,” “our,” “our company,” or
the “Company” refer to U.S. Stem Cell, Inc. and its
subsidiaries.
U.S. Stem Cell, Inc. (the “Company”) is pleased to announce that
Mark Borman has been appointed as Chairman of the Board of
Directors and William P. Murphy, Jr., M.D. has been bestowed with
the title of Chairman Emeritus, effective March 4, 2022.
Mr. Borman has served as a member of the Company’s Board of
Directors since May 2009. He is a seasoned financial officer with
more than 30 years of broad-based financial and investor relations
experience. Mr. Borman brings small-company entrepreneurial passion
and larger-company disciplines. In addition to the valuable
experience he gained working with entrepreneurs and their startups
from 2009 to present, Mr. Borman has experience with global,
NASDAQ- and NYSE-listed companies in various executive and
financial roles. He is currently a board member with public and
private technology companies and serves on advisory and
non-profit boards. During his career, Mr. Borman has held positions
with ADC Telecommunications, General Instrument Corporation, First
Chicago Corporation, FMC Corporation, Price Waterhouse, and KPMG.
Mr. Borman received his B.A. in Accounting from Michigan State
University and his M.B.A. in Finance from the University of Chicago
Booth School of Business. He is an Audit Committee Financial
Expert under SEC rules, a Certified Public Accountant and Chartered
Financial Analyst. Mr. Borman is a Board Leadership Fellow and
member of the National Association of Corporate Directors.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934 the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Registrant
Date: March 9, 2022
|
|
U.S. Stem Cell, Inc.
By: /s/ Michael Tomas
|
|
|
Michael Tomas
|
|
|
Chief Executive Officer
|
NONE false 0001388319
0001388319 2022-03-04 2022-03-04